Insiders who reported open-market trades in the last 12 months at the companies Carl L. Gordon files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Simeon George - $27.20M in ADRX purchases and sales in the last 12 months
Carl L. Gordon is a corporate insider, tracked as Director, 10% Owner of ADARx Pharmaceuticals, Inc. (ADRX). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Carl L. Gordon submitted recently?
4 primary Form 4 filings in the last 90 days, covering 3 companies.
Has Carl L. Gordon been buying or selling stock?
Recorded transactions: 7 open-market purchases ($61.15M) and 1 open-market sale ($5.68M) across all tracked filings.
Carl L. Gordon is Director, 10% Owner of ADARx Pharmaceuticals, Inc. (ADRX). 11 SEC Form 4 filings on record going back to 2024, most recently on 30 September 2026. Most recent open-market trade: bought $10.00M of ADRX on 30 September 2026. Lifetime open-market purchases: $61.15M. Lifetime open-market sales: $5.68M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Carl L. Gordon.
InsiderAlpha's records for Carl L. Gordon go back to 2024: 11 primary Form 4 filings, an average of 3.7 per year. The typical open-market purchase is $8.74M (7 buys totaling $61.15M). The largest single buy on record is $15.00M of SCTX in 2026. Sales side: 1 recorded sale totaling $5.68M, so the filing history runs buy-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
